PMID- 21801387
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20111110
LR  - 20211020
IS  - 1472-6823 (Electronic)
IS  - 1472-6823 (Linking)
VI  - 11
DP  - 2011 Jul 29
TI  - Impact of newly diagnosed abnormal glucose regulation on long-term prognosis in 
      low risk patients with ST-elevation myocardial infarction: A follow-up study.
PG  - 14
LID - 10.1186/1472-6823-11-14 [doi]
AB  - BACKGROUND: Patients with acute myocardial infarction and newly detected abnormal 
      glucose regulation have been shown to have a less favourable prognosis compared 
      to patients with normal glucose regulation. The importance and timing of oral 
      glucose tolerance testing (OGTT) in patients with acute myocardial infarction 
      without known diabetes is uncertain. The aim of the present study was to evaluate 
      the impact of abnormal glucose regulation classified by an OGTT in-hospital and 
      at three-month follow-up on clinical outcome in patients with acute ST elevation 
      myocardial infarction (STEMI) without known diabetes. METHODS: Patients (n = 224, 
      age 58 years) with a primary percutanous coronary intervention (PCI) treated 
      STEMI were followed for clinical events (all-cause mortality, non-fatal 
      myocardial re-infarction, recurrent ischemia causing hospital admission, and 
      stroke). The patients were classified by a standardised 75 g OGTT at two time 
      points, first, at a median time of 16.5 hours after hospital admission, then at 
      three-month follow-up. Based on the OGTT results, the patients were categorised 
      according to the WHO criteria and the term abnormal glucose regulation was 
      defined as the sum of impaired fasting glucose, impaired glucose tolerance and 
      type 2-diabetes. RESULTS: The number of patients diagnosed with abnormal glucose 
      regulation in-hospital and at three-month was 105 (47%) and 50 (25%), 
      respectively. During the follow up time of (median) 33 (27, 39) months, 58 
      (25.9%) patients experienced a new clinical event. There were six deaths, 15 
      non-fatal re-infarction, 33 recurrent ischemia, and four strokes. Kaplan-Meier 
      analysis of survival free of composite end-points showed similar results in 
      patients with abnormal and normal glucose regulation, both when classified 
      in-hospital (p = 0.4) and re-classified three months later (p = 0.3). 
      CONCLUSIONS: Patients with a primary PCI treated STEMI, without previously known 
      diabetes, appear to have an excellent long-term prognosis, independent of the 
      glucometabolic state classified by an OGTT in-hospital or at three-month 
      follow-up. TRIAL REGISTRATION: The trial is registered at 
      http://www.clinicaltrials.gov, NCT00926133.
FAU - Knudsen, Eva C
AU  - Knudsen EC
AD  - Center for Clinical Heart Research, Oslo University Hospital, Ulleval, Oslo, 
      Norway. Eva.Cecilie.Knudsen@ous-hf.no.
FAU - Seljeflot, Ingebjorg
AU  - Seljeflot I
FAU - Abdelnoor, Michael
AU  - Abdelnoor M
FAU - Eritsland, Jan
AU  - Eritsland J
FAU - Mangschau, Arild
AU  - Mangschau A
FAU - Muller, Carl
AU  - Muller C
FAU - Arnesen, Harald
AU  - Arnesen H
FAU - Andersen, Geir O
AU  - Andersen GO
LA  - eng
SI  - ClinicalTrials.gov/NCT00926133
PT  - Journal Article
DEP - 20110729
PL  - England
TA  - BMC Endocr Disord
JT  - BMC endocrine disorders
JID - 101088676
PMC - PMC3173358
EDAT- 2011/08/02 06:00
MHDA- 2011/08/02 06:01
PMCR- 2011/07/29
CRDT- 2011/08/02 06:00
PHST- 2011/03/15 00:00 [received]
PHST- 2011/07/29 00:00 [accepted]
PHST- 2011/08/02 06:00 [entrez]
PHST- 2011/08/02 06:00 [pubmed]
PHST- 2011/08/02 06:01 [medline]
PHST- 2011/07/29 00:00 [pmc-release]
AID - 1472-6823-11-14 [pii]
AID - 10.1186/1472-6823-11-14 [doi]
PST - epublish
SO  - BMC Endocr Disord. 2011 Jul 29;11:14. doi: 10.1186/1472-6823-11-14.